![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Enliven Therapeutics Inc | NASDAQ:ELVN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.57 | -2.32% | 24.01 | 18.91 | 28.50 | 24.63 | 23.43 | 24.30 | 151,673 | 21:14:53 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * 5AM Partners VI, LLC |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol Enliven Therapeutics, Inc. [ELVN] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below) | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 4838092 | I | By 5AM Ventures VI, L.P. (1) |
Common Stock | 960383 | I | By 5AM Opportunities I, L.P. (2) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
5AM Partners VI, LLC 501 2ND STREET, SUITE 350 SAN FRANCISCO, CA 94107 | X | ||||
5AM Ventures VI, L.P. 501 2ND STREET, SUITE 350 SAN FRANCISCO, CA 94107 | X | ||||
5AM Opportunities I (GP), LLC 501 2ND STREET, SUITE 350 SAN FRANCISCO, CA 94107 | X | ||||
5AM Opportunities I, L.P. 501 2ND STREET, SUITE 350 SAN FRANCISCO, CA 94107 | X | ||||
PARMAR KUSH C/O 5AM VENTURE MANAGEMENT, LLC 501 2ND STREET, SUITE 350 SAN FRANCISCO, CA 94107 | X |
Signatures | ||
5AM Partners VI, LLC, By /s/ Kush Parmar, Managing Member | 3/6/2023 | |
**Signature of Reporting Person | Date | |
5AM Ventures VI, L.P., By: 5AM Partners VI, LLC, its General Partner, By /s/ Kush Parmar, Managing Member | 3/6/2023 | |
**Signature of Reporting Person | Date | |
5AM Opportunities I (GP), LLC, By /s/ Kush Parmar, Managing Member | 3/6/2023 | |
**Signature of Reporting Person | Date | |
5AM Opportunities I, L.P., By: 5AM Opportunities I (GP), LLC, its General Partner, By /s/ Kush Parmar, Managing Member | 3/6/2023 | |
**Signature of Reporting Person | Date | |
/s/ Kush Parmar | 3/6/2023 | |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Enliven Therapeutics Chart |
1 Month Enliven Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions